Dataset Information

25-Hydroxycholesterol Inhibits KSHV and EBV Infections and Activates Inflammatory Cytokines

ABSTRACT: We previously demonstrated that 25HC (25-hydroxycholesterol, a derivative of cholesterol) blocks KSHV (Kaposi Sarcoma-associated Herpesvirus/ Human Herpesvirus-8) de novo infection of primary endothelial cells at a post-entry step and decreases viral gene expression. Herein we sought to determine transcriptomic changes associated with 25HC treatment of primary endothelial cells and primary B cells using RNA sequencing. To understand how 25HC inhibits KSHV infection, we examined global gene expression changes induced by 25HC in HUVECs, with or without KSHV infection. We pre-treated HUVEC with 25HC or vehicle control, then infected with KSHV (four conditions: -/+ 25HC, -/+ infection). At 2 days post-infection (dpi), we harvested RNA and performed RNA-seq to determine differentially expressed genes. We found that 25HC treatment inhibited KSHV gene expression globally and induced several inflammatory cytokines (CXCL8, IL1?), AP-1 components, and innate immunity receptors (RIG-I, TLR2) . Likewise, we also observed 25HC to block EBV de novo infection by inducing apoptosis and blocking transformation into lymphoblastoid cell lines. To determine transcriptomic changes that contributes to this, we purified B cells from healthy donors and infected them with EBV after 25HC pre-treatment with 4 similar conditions mentioned above. Samples were sent for RNA-Seq at 10-12 dpi. In contrast to KSHV infection, we found that only a subset of EBV viral transcripts are downregulated in the 25HC-treated samples. LMP1, which is the primary oncogenic factor, was suppressed and several downstream host targets that would prevent apoptosis during infection were likewise dysregulated. Additionally, several viral noncoding RNAs were also highly downregulated. Further analyses revealed that some 25HC-induced genes in our KSHV data set overlap with antiviral genes that were previously identified in various published screens involving other viruses, demonstrating the broad activity of 25HC. Together, these results answer some important questions about a widely acting antiviral (25HC), with implications for multiple viral and bacterial infections.

ORGANISM(S): Homo sapiens

PROVIDER: GSE165328 | GEO | 2021/11/24

REPOSITORIES: GEO

ACCESS DATA

Similar Datasets

Project description:Primary effusion lymphomas (PELs) are specifically associated with KSHV/HHV-8 infection, and most frequently occur in HIV-positive individuals as lymphomatous effusions in the serous cavities without a detectable solid tumor mass. Most PELs have concomitant EBV infection, suggesting that EBV is an important pathogenetic co-factor, although other as yet unidentified cofactors, such as cellular genetic alterations, are also likely to play a role. Lymphomatous effusions that lack KSHV also occur; these are frequently EBV-associated in the setting of HIV infection. Here we used gene expression profile analysis to determine the viral impact on cellular gene expression and the pathogenesis of these lymphomatous effusions. We used the Affymetrix HG-U133A microarray to analyze the gene expression profile of these effusion lymphomas (three virologic groups: KSHV-positive EBV-positive PELs, KSHV-positive EBV-negative PELs and KSHV-negative EBV-positive lymphomatous effusions). Nine cell lines derived from patients with lymphomatous effusions (three from each virologic group and each cell line was done in duplicates.) and three PEL patient samples were used in the study. Our results suggest that KSHV-positive PELs are very different from KSHV-negative lymphomatous effusions, and the genes that are differentially expressed include apoptosis regulators, cell cycle regulators, transcriptional factors and signal transduction regulators. KSHV clearly plays a dominant role in the phenotype of PEL. Within the KSHV-positive PELs, two subgroups can be identified, which were correlated with their EBV viral status. Among these genes (45 gene probes), four were regulators of the MAP kinase pathway that were up-regulated in the KSHV-positive, EBV-negative PELs, suggesting that in the absence of EBV, events that lead to the activation of the MAP kinase pathway may act as a cofactor for the development of PEL. Next we determined whether we could predict the viral status of the three primary patient cases of PEL based on the 45 gene probes that were differentially expressed in KSHV-positive cell lines according to EBV status (pt. 1: KSHV-positive, EBV-positive; Pt. 2: KSHV-positive, low proportion of EBV-positive; pt. 3: KSHV-positive EBV-negative), and we could. Samples: KSHV-positive EBV-positive cell lines: BC-1, BC-2, BC-5 KSHV-positive EBV-negative cell lines: BC-3, BCBL-1, PEL-5 KSHV-negative EBV-positive cell lines: IBL4, SM1, BCKN-1 Patient 1: KSHV-positive, EBV-positive Patient 2: KSHV-positive, EBV-positive (low number of positive cells) Patient 3: KSHV-positive, EBV-negative.

Project description:Primary effusion lymphomas (PELs) are specifically associated with KSHV/HHV-8 infection, and most frequently occur in HIV-positive individuals as lymphomatous effusions in the serous cavities without a detectable solid tumor mass. Most PELs have concomitant EBV infection, suggesting that EBV is an important pathogenetic co-factor, although other as yet unidentified cofactors, such as cellular genetic alterations, are also likely to play a role. Lymphomatous effusions that lack KSHV also occur; these are frequently EBV-associated in the setting of HIV infection. Here we used gene expression profile analysis to determine the viral impact on cellular gene expression and the pathogenesis of these lymphomatous effusions. We used the Affymetrix HG-U133A microarray to analyze the gene expression profile of these effusion lymphomas (three virologic groups: KSHV-positive EBV-positive PELs, KSHV-positive EBV-negative PELs and KSHV-negative EBV-positive lymphomatous effusions). Nine cell lines derived from patients with lymphomatous effusions (three from each virologic group and each cell line was done in duplicates.) and three PEL patient samples were used in the study. Our results suggest that KSHV-positive PELs are very different from KSHV-negative lymphomatous effusions, and the genes that are differentially expressed include apoptosis regulators, cell cycle regulators, transcriptional factors and signal transduction regulators. KSHV clearly plays a dominant role in the phenotype of PEL. Within the KSHV-positive PELs, two subgroups can be identified, which were correlated with their EBV viral status. Among these genes (45 gene probes), four were regulators of the MAP kinase pathway that were up-regulated in the KSHV-positive, EBV-negative PELs, suggesting that in the absence of EBV, events that lead to the activation of the MAP kinase pathway may act as a cofactor for the development of PEL. Next we determined whether we could predict the viral status of the three primary patient cases of PEL based on the 45 gene probes that were differentially expressed in KSHV-positive cell lines according to EBV status (pt. 1: KSHV-positive, EBV-positive; Pt. 2: KSHV-positive, low proportion of EBV-positive; pt. 3: KSHV-positive EBV-negative), and we could. Samples: KSHV-positive EBV-positive cell lines: BC-1, BC-2, BC-5 KSHV-positive EBV-negative cell lines: BC-3, BCBL-1, PEL-5 KSHV-negative EBV-positive cell lines: IBL4, SM1, BCKN-1 pt. 1: KSHV-positive, EBV-positive pt. 2: KSHV-positive, EBV-positive (low number of positive cells) pt. 3: KSHV-positive, EBV-negative Keywords: other

Dataset Information

25-Hydroxycholesterol Inhibits KSHV and EBV Infections and Activates Inflammatory Cytokines

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure